Table 2.
Prevalence profile of autoimmune liver disease in biliary atresia patients and non-biliary atresia controls n (%)
| Variable | BA, n = 81 |
Non-BA, n = 88 |
||
| Other liver diseases1, n = 44 | Healthy, n = 40 | Total | ||
| PBC-related antibodies | 15 (18.5)c | 4 (9.1) | 1 (2.5) | 5 (5.7) |
| AMA-M2 | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| Anti- BPO | 12 (14.8)ac | 2 (4.5) | 0 (0) | 2 (2.2) |
| Anti-Sp100 | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| Anti-gp210 | 2 (2.5) | 1 (2.3) | 1 (2.5) | 2 (2.2) |
| Anti-PML | 3 (3.7) | 1 (2.3) | 0 (0) | 1 (1.1) |
| AMA-M2 + anti-BPO | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| AMA-M2 + anti-BPO + anti-Sp100 + anti-PML | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| AIH-related antibodies | 6 (7.4) | 3 (6.8) | 3 (7.5) | 6 (6.8) |
| Anti-LKM-1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Anti-LC-1 | 5 (6.2) | 3 (6.8) | 3 (7.5) | 6 (6.8) |
| Anti-SLA/LP | 1 (1.2) | 0 (0) | 0 (0) | 0 (0) |
| Anti-Ro-52 | 5 (6.2) | 2 (4.5) | 2 (5) | 4 (4.5) |
1
Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls. AMA-M2 + M2-3E: combined the positivity to AMA-M2 and BPO; AMA-M2 + BPO + Sp100 + PML: Combined the positivity to AMA-M2, BPO, Sp100, and PML.
c
P < 0.05 vs non-BA;
a
P < 0.05 vs healthy controls. AIH: Autoimmune hepatitis; BA: Biliary atresia; PBC: Primary biliary cholangitis; LKM-1: Liver-kidney microsomal type 1; LC-1: Liver cytosolic antigen type 1.